Darcis, G, Van Driessche, B, Van Lint, C, HIV latency: should we shock or lock?. Trends Immunol 38 (2017), 217–228.
Saez-Cirion, A, Bacchus, C, Hocqueloux, L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog, 9, 2013, e1003211.
Frange, P, Faye, A, Avettand-Fenoel, V, et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3 (2016), e49–e54.
Kinloch-de Loes, S, Dorrell, L, Yang, H, et al. Aviremia 10 Years Postdiscontinuation of antiretroviral therapy initiated during primary human immunodeficiency virus-1 infection and association with gag-specific T-cell responses. Open Forum Infect Dis, 2, 2015, ofv144.
Fletcher, CV, Staskus, K, Wietgrefe, SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 111 (2014), 2307–2312.
Lorenzo-Redondo, R, Fryer, HR, Bedford, T, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530 (2016), 51–56.
Hatano, H, Strain, MC, Scherzer, R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 208 (2013), 1436–1442.
Lorenzo-Redondo, R, Fryer, HR, Bedford, T, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530 (2016), 51–56.
Latini, A, Fabbiani, M, Borghi, V, et al. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infect Dis, 16, 2016, 401.
Gubavu, C, Prazuck, T, Niang, M, et al. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother 71 (2016), 1046–1050.
Capetti, AF, Sterrantino, G, Cossu, MV, et al. Switch to dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort. PLoS One, 11, 2016, e0164753.
Perez-Molina, JA, Rubio, R, Rivero, A, et al. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother 72 (2017), 246–253.
Lombardi, F, Belmonti, S, Quiros-Roldan, E, et al. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. J Antimicrob Chemother, 2017 published online March 10. DOI:10.1093/jac/dkx068.
